About 11,517,692 results

COSMIC-021 Data Affirm Activity of Cabozantinib/Atezolizumab in mCRPC

Jun 7th, 2020

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma

May 31st, 2020

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer

Jun 1st, 2020

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer

May 31st, 2020

CD71-Directed Probody-Drug Conjugate Shows Safety, Signals of Activity in Advanced Solid Tumors

Jun 1st, 2020

Pevonedistat/Azacitidine Shows Favorable Activity in Higher-Risk MDS/CMML, Low-Blast AML

Jun 2nd, 2020

Addition of Veliparib to Cisplatin Significantly Improves PFS in BRCA-Like Advanced TNBC

Jun 1st, 2020

Dr. Rodriguez-Abreu on the Final Analysis of the KEYNOTE-189 Trial in NSCLC

May 31st, 2020

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC

May 31st, 2020

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL

May 31st, 2020

Steroid drug hailed as 'breakthrough' for seriously ill COVID-19 patients

A cheap and widely used steroid called dexamethasone has become the first drug shown to be able to save the lives of COVID-19 patients in what scientists said is a “major breakthrough” in the coronavirus pandemic.

Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic

Individuals with Familial Hypercholesterolaemia (FH) are at very high risk of cardiovascular disease, which is associated with poor outcomes from coronavirus infections. COVID-19 puts strain on healthcare systems and may impair access to routine FH services. On behalf of the International Lipid Expert Panel (ILEP) and the European FH Patient Network (FH Europe), we present brief recommendations...

Familial hypercholesterolaemia and COVID‐19: triggering of increased sustained cardiovascular risk

Early data from Wuhan, China, show that patients with COVID‐19 are typically male, aged 40 to 60 years, and about one‐third have comorbidities. Moreover, of 138 COVID‐19 patients hospitalized in Wuhan and treated in an intensive care unit (ICU), 25% had cardiovascular disease and 58% hypertension; the respective figures for non‐ICU‐treated COVID‐19 patients were10% and 22% [1]. Based on these e...

Recovering patient volume and practice finances in the wake of COVID-19: 12 tips

Nationally, patient volume has dropped 60%(www.medscape.com) since the start of the pandemic and is now rebounding, either gradually or rapidly depending on local circumstances. However, practices are unlikely to return to normal volumes for some time as patients continue to avoid the office and as offices continue to keep high-risk patients at home and treat them via telehealth. These changes ...

Plasminogen improves lung lesions and hypoxemia in patients with COVID-19

Lungs from patients with coronavirus disease 2019 (COVID-19) have shown typical signs of acute respiratory distress syndrome (ARDS), formation of hyaline membrane mainly composed of fibrin and ‘ground-glass’ opacity. Previously, we showed plasminogen itself is a key regulator in fibrin degradation, wound healing and infection.

After patient volume collapsed amid the coronavirus pandemic, some see signs of recovery

Overall patient volumes declined at hospitals by more than 50% amid the coronavirus pandemic. Outpatient volumes may be beginning to turn around as hospitals restart elective procedures. Hospitals face challenges in restarting elective procedures, including staffing, equipment and patient fears. Hospital patient volumes declined steeply in March and April amid mass suspension of elective pro...

People Who Are at Higher Risk for Severe Illness

COVID-19 is a new disease and there is limited information regarding risk factors for severe disease. Based on currently available information and clinical expertise, older adults and people of any age who have serious underlying medical conditions might be at higher risk for severe illness from COVID-19.

Coronavirus: Physician survey finds patient volumes down, likely to stay down for a year

Patient volumes are down for physicians due to the COVID-19 coronavirus pandemic and it is expected they will continue to be down for the next year, according to a new survey from Piper Sandler.

Can a toilet promote virus transmission? From a fluid dynamics perspective

Currently, a novel coronavirus named “SARS-CoV-2” is spreading rapidly across the world, causing a public health crisis, economic losses, and panic. Fecal–oral transmission is a common transmission route for many viruses, including SARS-CoV-2. Blocking the path of fecal–oral transmission, which occurs commonly in toilet usage, is of fundamental importance in suppressing the spread of viruses. H...

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

We present severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) real-time RT-PCR results of all respiratory and faecal samples from patients with coronavirus disease 2019 (COVID-19) at the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China, throughout the course of their illness and obligated quarantine period.